All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Ongoing | 2013-000798-59 | Phase III, open-label, multi-centre study to assess the pharmacodynamic (PD), pharmacokinetic (PK) and safety of Zoreline 3.6 mg goserelin subcutaneous implant (Novalon) in women with confirmed endome... | not-yet-due | |
| Reported results | 2013-000799-14 | Phase III, open-label, multi-center study to assess the pharmacodynamic (PD), pharmacokinetic (PK) and safety of Zoreline 10.8 mg goserelin subcutaneous implant (Novalon) in male patients with prostat... | 2016-05-03 | due-trials |
| Reported results | 2015-001756-30 | Open-label, multi-center, randomized parallel group study to assess the pharmacokinetic (PK) profile of Zoreline 10.8 mg goserelin subcutaneous implant (test product, Novalon S.A.) and of Zoladex® LA ... | 2017-03-08 | due-trials |
| Reported results | 2015-005124-25 | Open-label, multi-center, randomized parallel group study to assess the pharmacokinetic (PK) profile of Zoreline 3.6 mg goserelin subcutaneous implant (test product, Novalon S.A.) and of Zoladex® 3.6 ... | 2017-10-26 | due-trials |
| Reported results | 2019-000593-32 | Phase III, open-label, multi-center study to assess the pharmacodynamic (PD), pharmacokinetic (PK) and safety of Zoreline 10.8 mg goserelin subcutaneous implant (Novalon) in male subjects with prostat... | 2020-04-06 | due-trials |